AXSM (Axsome Therapeutics) Long-Term Debt: $117.9 Mil (As of Mar. 2026)


AXSM Axsome Therapeutics Inc AXSM
52 GF Score
Price $248.26
GF Value $220.41
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Long-Term Debt?

Axsome Therapeutics AXSM +2.96% 52 Long-Term Debt is $117.9 Mil as of Mar. 2026. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $220.41 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Axsome Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $117.9 Mil.

Axsome Therapeutics's quarterly Long-Term Debt increased from Sep. 2025 ($117.6 Mil) to Dec. 2025 ($117.7 Mil) and increased from Dec. 2025 ($117.7 Mil) to Mar. 2026 ($117.9 Mil).

Axsome Therapeutics's annual Long-Term Debt increased from Dec. 2023 ($178.1 Mil) to Dec. 2024 ($180.7 Mil) but then declined from Dec. 2024 ($180.7 Mil) to Dec. 2025 ($117.7 Mil).

Axsome Therapeutics  (NAS:AXSM) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Axsome Therapeutics Long-Term Debt Related Terms

Axsome Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics Long-Term Debt Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.09 94.26 178.07 180.71 117.75

Axsome Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 181.38 117.54 117.64 117.75 117.85
AXSM
52GF Score
Axsome Therapeutics Inc AXSM
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $117.9 Mil mean?
Axsome Therapeutics (AXSM) has a Long-Term Debt of $117.9 Mil as of Mar. 2026.
Is Axsome Therapeutics' Long-Term Debt too high?
Axsome Therapeutics' current Long-Term Debt is $117.9 Mil. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Long-Term Debt compare to MDGL and IONS?
Axsome Therapeutics' Long-Term Debt of $117.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Axsome Therapeutics's current Long-Term Debt is $117.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Modestly Overvalued. The stock's GF Value™ is $220.41, compared to a current price of $248.26 — trading 12.6% above its estimated fair value. The current Long-Term Debt is $117.9 Mil. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current Long-Term Debt is $117.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $248.26 is trading 12.6% above its estimated GF Value™ of $220.41. GuruFocus considers Axsome Therapeutics to be Modestly Overvalued.

Key valuation signals for AXSM:

  • Long-Term Debt: $117.9 Mil
  • GF Value™: $220.41 vs. price of $248.26 (12.6% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for AXSM

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$248.26
Price
$220.41
GF Value